It’s a tale of two biotech firms this afternoon, as shares of TrovaGene Inc (NASDAQ:TROV) are up $0.73, or 20%, at $4.
Cantor analyst Sung Ji Nam has high hopes for Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG), upgrading shares to Buy and raising the price target to …
Zacks analyst Grant Zeng was out pounding the table on Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG), reiterating an Outperform rating and a $10.
